Expanded access to publicly subsidised lisdexamfetamine treatment for adults with attention-deficit/hyperactivity disorder: An interrupted time-series analysis

Aust N Z J Psychiatry. 2023 Jul;57(7):1073-1076. doi: 10.1177/00048674231170556. Epub 2023 Apr 25.
No abstract available

Publication types

  • Letter

MeSH terms

  • Adult
  • Attention Deficit Disorder with Hyperactivity* / drug therapy
  • Central Nervous System Stimulants* / therapeutic use
  • Dextroamphetamine / therapeutic use
  • Dose-Response Relationship, Drug
  • Double-Blind Method
  • Humans
  • Lisdexamfetamine Dimesylate / therapeutic use
  • Treatment Outcome

Substances

  • Lisdexamfetamine Dimesylate
  • Central Nervous System Stimulants
  • Dextroamphetamine